2021 Online, In the cloud

II-01 Noha Abdelgawad
Population pharmacokinetics of pyrazinamide in hospitalised TB patients with HIV versus TB outpatients
II-02 Mahmoud Abdelwahab
Population Pharmacokinetic/Pharmacodynamic Modelling of Clofazimine Effects on QTcF in South African tuberculosis patients
II-03 Leticia Arrington
Evaluation of IRT-derived disease severity as a predictor of clinical success in critically ill patients with severe antibiotic resistant infections
II-04 Fauke Assmus
Population pharmacokinetics of benznidazole as monotherapy and in combination with fosravuconazole in adult patients with chronic Chagas disease (BENDITA study)
II-05 Ahmad Rami Ayoun Alsoud
Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data
II-06 Irina Bondareva
Population pharmacokinetics of meropenem in adult intensive care unit (ICU) patients estimated from therapeutic drug monitoring data (TDM) data
II-07 Unai Caballero
Pharmacokinetic/pharmacodynamic modelling and simulation of the in vitro activity of isavuconazole and echinocandin combination against Candida auris.
II-08 Lu Chen
Pharmacokinetics of fluconazole in obese and non-obese adults upon a semi-simultaneous oral and IV study design
II-09 Palang Chotsiri
Piperaquine pharmacokinetics during intermittent preventive treatment for malaria in pregnancy
II-10 Selma El Messaoudi
A mechanistic model to characterize the long-term dynamic of HBV markers in Lamivudine and PEG-IFNa treated patients
II-11 Teresa Garcia
Non-linear binding model of total daptomycin in patients with normal and impaired renal function
II-12 Kamunkhwala Gausi
Pharmacokinetics of high dose isoniazid among individuals with multidrug-resistant tuberculosis
II-13 Victória Etges Helfer
Population pharmacokinetic modeling of ceftaroline characterizing tissue distribution following different ceftaroline fosamil infusion regimens to volunteers undergoing muscle and subcutaneous tissue microdialysis
II-14 Richard Höglund
Pharmacokinetics and pharmacodynamics of ivermectin and its metabolites
II-15 Aida Kawuma
Rifabutin changes dolutegravir’s half-life but not area under the curve when co-administered
II-16 Guillaume Lingas
Lassa viral dynamics in macaques treated with favipiravir or ribavirin
II-17 Feiyan Liu
Modeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations
II-18 Nele Mueller-Plock
Predicting RSV efficacy for moderate and tropical climates considering seasonal differences in RSV force-of-infection – Application of an MBMA and clinical trial simulation framework to support MK-1654 decision making
II-19 Anh Duc Pham
Modelling rate and extent of resistance development against colistin in Klebsiella pneumoniae
II-20 Viktor Rognĺs
Turn-over model characterizing effect of colistin on serum-creatinine in critically ill patients
II-21 Federico Romano
Model-based extrapolation of the early bacterial activity (EBA) of bedaquiline-combination regimens for the treatment of pulmonary tuberculosis
II-22 Louis Sandra
A target-mediated drug disposition model describing plasma and liver pharmacokinetics of JNJ-73763989 in AAV-HBV mice
II-23 Hiie Soeorg
Prediction of C-reactive protein dynamics during meropenem treatment in very-low-birth-weight neonates with late-onset sepsis or pneumonia
II-24 Jesper Sundell
Model-based characterization of drug-drug interaction between isoniazid and rifampicin
II-25 Lénaďg Tanneau
Population pharmacokinetics of delamanid and its main metabolite DM-6705 in patients with multidrug resistant tuberculosis
II-26 David Uster
Evaluation of four distinct weighting schemes in a model averaging and selection approach in model-informed precision dosing of continuously infused vancomycin
II-27 Stijn van Beek
Modeling the relationship between plasma and intracellular pharmacokinetics of bedaquiline and its metabolite M2 in South African patients with rifampicin-resistant tuberculosis
II-28 Luka Verrest
Pharmacokinetic-pharmacodynamic modelling of Leishmania blood parasite kinetics in visceral leishmaniasis patients
II-29 Qianwen Wang
Determination of risk factors for time to culture conversion in tuberculosis patients receiving novel regimen
II-30 Thanaporn Wattanakul
Semi-mechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
II-31 Justin Wilkins
PK/PD modelling of M5717 in malaria
II-32 Tan Zhang
A population pharmacokinetic analysis to evaluate the impact of body weight, renal function, and patient status on vancomycin pharmacokinetics
II-33 Marcus Baaz
Evaluation and Optimization of Model-based Translations in Oncology - From Xenografts to RECIST
II-35 Elisa Borella
PKPD modelling of MEN1611 anti-tumor effect in xenograft models to predict efficacy threshold concentrations in HER2-positive advanced or metastatic breast cancer patient population
II-36 Aurore CARROT
Population K-PD modelling of PSA kinetics in patients with recurrent prostate cancer.
II-37 Marc Cerou
A model-based approach to evaluate the effect of isatuximab in combination with pomalidomide and dexamethasone using multiple composite endpoints: Application to the ICARIA study in relapsed/refractory multiple myeloma
II-38 Pascal Chanu
A disease model for Multiple Myeloma developed using Real World Data
II-39 Jonathan Chauvin
A library of tumor growth and tumor growth inhibition models for the MonolixSuite
II-40 Wan-Yu Chu
Elucidating the effect of platelet binding on vincristine distribution by a physiologically based pharmacokinetic (PBPK) approach
II-41 David Damoiseaux
Predictiveness of the human CYP3A4 transgenic mouse model (Cyp3aXAV) for human drug exposure assessed using a population pharmacokinetic approach
II-42 Nikki de Rouw
Costs of pemetrexed-associated neutropenia and the budget impact of pemetrexed dose individualization
II-43 Carlos Fernandez-Teruel
Population Pharmacokinetics of Capivasertib, a Potent Selective AKT Inhibitor, in Patients with Solid Tumours
II-44 David Hodson
Non linear mixed effects modelling of tumour interactions with the adaptive immune response during Radiotherapy in combination with anti-PDL1 or Olaparib.
II-45 Eman Ibrahim
Pharmacokinetic-pharmacodynamic (PK-PD) modeling of leukocyte dynamics and lymph node size in chronic lymphocytic leukaemia patients treated with ibrutinib
II-46 Itziar Irurzun Arana
Ceralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination
II-47 Martin Johnson
Long short-term memory recurrent neural networks to predict longitudinal changes in tumour size
II-48 Yoshimasa Kobayashi
Pharmacometric analysis to justify a higher recommended dose for trastuzumab deruxtecan in the treatment of subjects with metastatic gastric cancer versus breast cancer
II-49 Naoki Kotani
A model based approach to infer overall survival (OS) in hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (HR+/HER2- mBC)
II-50 Nataliya Kudryashova
The Markov chain survival modeling platform for cancer burden assessment
II-51 Rachael Lawson
Development of a time dependent clearance model for busulfan in paediatric patients to investigate dosing adjustment scenarios
II-52 Xia Li
Population-based Target-Mediated Drug Disposition (TMDD) Pharmacokinetics Model of Daratumumab in Patients With Multiple Myeloma Following Intravenously Daratumumab Monotherapy
II-53 Sarah Lobet
Target-mediated pharmacokinetics of cetuximab: target occupancy influences progression-free survival
II-54 Paolo Magni
Reduced food-intake and sarcopenia in animal models of cancer anorexia-cachexia syndrome: a Dynamic Energy Budget (DEB)-based modeling approach
II-55 Luca Marzano
Role of tree-based machine learning algorithms in prognostic pattern detection: an Extensive-Disease Small Cell Lung Cancer (ED-SCLC) study
II-56 Zinnia Parra-Guillen
Mechanistic modeling of a novel oncolytic virus, V937, to describe viral kinetic and dynamic processes following intratumoral and intravenous administration
II-57 Clémence Pouzin
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate.
II-58 Alicja Puszkiel
Optimisation of the dose and schedule of everolimus and sorafenib combination therapy in patients with solid tumors using a PKPD/time-to-event model
II-59 Thomas RODIER
Population Pharmacokinetic-Pharmacogenetic Analysis of Osimertinib in patients with Non-Small Cell Lung Cancer
II-60 Aymara Sancho
Semi-mechanistic model for the antitumor response of a combination cocktail of immune-modulators in non-inflamed (cold tumors)
II-61 Eduard Schmulenson
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)
II-62 Gianluca Selvaggio
Computational analysis of cytokine release following bispecific T-cell engager therapy
II-63 Hinke Siebinga
A Population Pharmacokinetic Model to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients
II-64 Alexandra Smirnova
Dose dependence of safety of PD-1 and CTLA-4 checkpoint inhibitors: Comparison of normal-normal and binomial-normal hierarchical models for rare events in a Bayesian meta-analysis framework
II-65 Alina Sofronova
The multivariate baseline and longitudinal biomarker analysis for the survival prediction in NSCLC by means of joint modeling
II-66 Xuyang SONG
Population Pharmacokinetics Modeling of Monalizumab in Cancer Patients with Longitudinal Patient/Disease Characteristics
II-67 Maximilian Strobl
Adaptive therapy: Leveraging eco-evolutionary principles to improve resistance management in oncology
II-68 Elena Tosca
A tumor-in-host Dynamic Energy Budget (DEB)-based paradigm for preclinical to clinical translation: predictions of tumor-in-host growth dynamics
II-69 Armando Tratenšek
Target-mediated drug disposition model of rituximab in patients with diffuse large B-cell lymphoma
II-70 Van Thuy Truong
A comparison of ordinary differential equation and agent-based approaches to PKPD modelling in oncology
II-71 Vianney Tuloup
Drug exposure prediction in renal impaired patient: an IMSM approach
II-72 Maarten Van Eijk
Pharmacokinetic and pharmacodynamic modelling of different oral paclitaxel formulations co-administered with ritonavir.
II-73 Elena Vasileva
Pharmacokinetic, receptor occupancy and pharmacodynamic (PK/RO/PD) modeling of ALX148, a CD47 blocker
II-74 Julie Dudasova
A method to estimate probability of disease and vaccine efficacy from clinical trial immunogenicity data
II-75 Undine Falkenhagen
Reducing QSP models to derive mechanism-based PD models: warfarin-INR as an example
II-76 Sergey Gavrilov
Survival Model-based Meta-Analysis Framework for the Indirect Comparison of Anti-Cancer Therapy Efficacy
II-77 Mohamed Gewily
Model Averaging Across Parametric and Non-Parametric Methods as an Aid for Clinical Decision Making
II-78 Elham Haem
Comparison of the power and type-1 error of composite score models for drug effect detection in clinical trials
II-79 Vincent Hurez
Development of a systemic lupus erythematosus (SLE) QSP model linking systemic biomarkers to cutaneous clinical score (CLASI) outcomes.
II-80 Mutaz Jaber
Investigating Components of Residual Unexplained Variability in Nonlinear Mixed-Effect Modeling
II-81 Daniel Kaschek
Crossing borders from mechanistic QSP to clinical population modeling
II-82 Aurélie Lereclus
Lithium pharmacometrics: review of population pharmacokinetics models, external evaluation using non compartmental literature data and model’s updating based on straightforward integration of glomerular filtration rate.
II-83 Klaus Lindauer
Evaluation of random forest as an approach for covariate selection
II-84 Dan Lu
Machine and deep learning approaches for disease progression modeling: illustration with geographic atrophy
II-85 Moustafa M. A. Ibrahim
Enhancing Efficiency and Decision Quality in Parkinson’s Disease Drug Trials for LRRK2 Programs Using Item Response Modelling
II-86 Rikard Nordgren
Pharmpy and assemblerr - Two novel tools to simplify the model building process in NONMEM
II-87 Raman Sharma
A probabilistic approach to calculating probability of achieving target pharmacological effect levels for a novel orally administered antibacterial chemotherapeutic
II-89 Gustaf Wellhagen
Item Response Theory-Informed Total Score Analysis
II-90 Xiao Zhu
Positive allosteric modulators - a challenge for development of QSP models